更新于：2024-11-01

Scurvy

坏血病

更新于：2024-11-01

基本信息

别名

HYPOASCORBEMIA、Hypoascorbemia、Hypoascorbemias

+ [14]

简介

An acquired blood vessel disorder caused by severe deficiency of vitamin C (ASCORBIC ACID) in the diet leading to defective collagen formation in small blood vessels. Scurvy is characterized by bleeding in any tissue, weakness, ANEMIA, spongy gums, and a brawny induration of the muscles of the calves and legs.

关联

项与坏血病相关的药物

Ascorbic Acid

维生素C

靶点-

作用机制

维生素C补充剂

在研机构

McGuff Pharmaceuticals, Inc. [+35]

原研机构

宜昌人福药业有限责任公司

在研适应症

维生素缺乏 [+22]

非在研适应症

喂食及进食障碍 [+4]

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1981-01-01

项与坏血病相关的临床试验

NCT05733078 / Recruiting临床2期IIT

Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism Requiring High Levothyroxine Dosage; a Randomized Control Trial

Thyroid disease affects almost a quarter of a billion individuals worldwide and more than 50% of them being not aware of this condition. The commonest thyroid disease is iodine deficiency related thyroid dysfunction with nearly 2 billion people around the globe at risk with insufficient iodine intake. Autoimmune thyroid disorders are commonest cause of thyroid dysfunction in iodine sufficient parts of the world. Sub-optimally or untreated hypothyroidism can lead to cognitive decline, dyslipidemia, hypertension, infertility as well as cardiovascular and neuromuscular problems. The prevalence of hypothyroidism can vary in general population with up-to 5.3% people with overt hypothyroidism based on studies from the West, with estimated 10% of the population having subclinical hypothyroidism globally. In the gulf region however, there are no national studies that provide insight into exact prevalence of hypothyroidism, however some cross-sectional screening studies indicate frequency of hypothyroidism to be as high as 5-10%.
Levothyroxine is a synthetic hormone with structure similar to naturally occurring thyroxine, and it is used as replacement monotherapy of hypothyroidism. It is mainly absorbed via small intestine. The optimal daily levothyroxine dosage requirement is 1.6 microgram/kg body weight/day, which can normalize TSH in most patients, however many studies indicate that nearly half the patient on replacement therapy may not attain a normal TSH and require further doses, possibly due to interference or malabsorption. Multiple dose change and repeated diagnostic procedures in these patients can not only increased health costs but increased of ensuing complications secondary to sub-optimally controlled hypothyroidism. Instead of increasing levothyroxine doses and getting variable response, recent study have shown improvement in thyroid function by adding on vitamin C alongside levothyroxine dose, albeit only in a specific subset of patient having gastritis. The effect of Vitamin C on improving levothyroxine also been shown to be effective over a short period in a non-randomized, non-controlled setting. Our study aims to investigate whether addition of vitamin C to levothyroxine can improve the biochemical and clinical thyroid status in a randomized controlled setting.

开始日期2023-11-01

申办/合作机构

United Arab Emirates University

ACTRN12623000020684 / Not yet recruiting临床2期IIT

Can personalised antioxidant screening and prescription improve cardiovascular and metabolic health in individuals with pre-diabetes and type 2 diabetes: PRESCRIBE.

开始日期2023-08-14

申办/合作机构

Deakin University

ACTRN12622001367730 / Not yet recruitingN/AIIT

Investigating the metabolic conversion of crab apple-derived ascorbyl 2-beta-glucoside (AA2ßG) to Vitamin C by characterising the bioavailability of Vitamin C after consuming a single dose of crab apple juice in healthy individuals

开始日期2023-01-23

申办/合作机构-

100 项与坏血病相关的临床结果

登录后查看更多信息

100 项与坏血病相关的转化医学

登录后查看更多信息

0 项与坏血病相关的专利（医药）

登录后查看更多信息

1,801

项与坏血病相关的文献（医药）

2024-11-01·International Journal of Biological Macromolecules

Exploring Rosa roxburghii Tratt polysaccharides: From extraction to application potential in functional products - An in-depth review

Review

作者: Tao, Aien ; Yin, Chenglong ; Zhang, Lingsheng ; Yang, Yongcheng ; Zhong, Xuehua ; Tian, Yongjie ; Zhang, Yue ; Fang, Xiao

Rosa roxburghii Tratt (R. roxburghii), a unique ethnic medicine native to southwest China, is classified as both medicinal and culinary, offering a multitude of health benefits. Traditionally, it is used to eliminate diet and relieve diarrhea, nourish Yin and invigorate the spleen, dispel wind and dampness, enhance immunity, and promote the healthy development of the body. Furthermore, it serves as a remedy for ailments such as scurvy, night blindness, cancer, hyperlipidemia, hyperglycemia, and hypertension. R. roxburghii contains many nutritious and active ingredients, including proteins, vitamin C, inorganic salts, essential amino acids, polysaccharides, phenols, triterpenes, organic acids, and superoxide dismutase (SOD). Among them, polysaccharides stand out as pivotal bioactive components, comprising mannose, ribose, rhamnose, glucosamine hydrochloride, glucuronic acid, galacturonic acid, glucose, galactose, arabinose, and fucose, among others. R. roxburghii polysaccharides (RTFPs) present diverse biological activities, including antioxidant, anti-fatigue, hypoglycemic, anti-tumor, immune modulation, relief from ulcerative colitis, protection of neural stem cells from glutamate damage, and improvement of intestinal micro-ecology. Due to its distinctive bioactivity, the research on RTFPs is booming. While numerous extraction and purification techniques have successfully isolated and characterized RTFPs, comprehensive understanding of their chemical structure, mechanisms, structure-activity relationships, safety profiles, and practical applications remains limited. This knowledge gap hampers their optimal utilization and development. In response, this research offers an overview of extraction, purification, structure characteristics, biological activities, structure-activity relationships, and pharmaceutical application of RTFPs. Additionally, this research not only lays a theoretical basis for the comprehensive exploration and exploitation of R. roxburghii and its polysaccharide resources but also offers extensive knowledge and insights into the development and application of RTFPs as a novel functional foods and drugs.

2024-11-01·Nutrition Reviews

Prevalence, risk factors, and clinical outcomes of vitamin C deficiency in adult hospitalized patients in high-income countries: a scoping review

Review

作者: Lemoh, Christopher N ; Bauer, Judith D ; Davidson, Zoe E ; Gibson, Simone J ; Golder, Janet E ; Barker, Lisa A

AbstractBackgroundAssessment for vitamin C deficiency (VCD) is rarely undertaken in an acute hospital setting in high-income countries. However, with growing interest in VCD in community settings, there is emerging evidence investigating the prevalence and impact of VCD during hospitalization.ObjectivesIn this scoping review, the prevalence of VCD in adult hospitalized patients is explored, patient characteristics are described, and risk factors and clinical outcomes associated with VCD are identified.MethodsA systematic scoping review was conducted in accordance with the PRISMA-ScR framework. The Ovid MEDLINE, Ovid Embase, Scopus, CINAHL Plus, Allied and Complementary Medicine Database, and the Cochrane Library databases were searched for interventional, comparative, and case-series studies that met eligibility criteria, including adult hospital inpatients in high-income countries, as defined by the Organization for Economic Co-operation and Development, that reported VCD prevalence using World Health Organization reference standards. These standards define VCD deficiency as plasma or serum vitamin C level <11.4 µmol/L, wholeblood level <17 µmol/L, or leukocytes <57 nmol/108 cells.ResultsTwenty-three articles were included, representing 22 studies. The cumulative prevalence of VCD was 27.7% (n = 2494; 95% confidence interval [CI], 21.3-34.0). High prevalence of VCD was observed in patients with severe acute illness and poor nutritional status. Scurvy was present in 48% to 62% of patients with VCD assessed in 2 studies (n = 71). Being retired (P = 0.015) and using excessive amounts of alcohol and tobacco (P = 0.0003) were independent risk factors for VCD (n = 184). Age was not conclusively associated with VCD (n = 631). Two studies examined nutrition associations (n = 309); results were inconsistent. Clinical outcomes for VCD included increased risk of frailty (adjusted odds ratio, 4.3; 95%CI, 1.33–13.86; P = 0.015) and cognitive impairment (adjusted odds ratio, 2.93; 95%CI, 1.05–8.19, P = 0.031) (n = 160).ConclusionsVCD is a nutritional challenge facing the healthcare systems of high-income countries. Research focused on early identification and treatment of patients with VCD is warranted.Systematic Review RegistrationOpen Science Framework ( https://doi.org/10.17605/OSF.IO/AJGHX ).

2024-10-07·Canadian Medical Association Journal

Scurvy in a 65-year-old woman with severely limited function and social supports

Article

作者: Murray, Kevin R. ; Cagliero, Diana ; Murray, Kevin R ; Engelhart, Sarah ; Kiebalo, Thomas

项与坏血病相关的新闻（医药）

2024-06-29

·蒲公英Ouryao

【出海新进展】7药品出口亚洲、欧洲多国

来源：企业公告编辑：wangxinglai2004 近日，4药企分别发布了产品海外上市进展公告，具体为汇宇制药三注射剂药品出口乌兹别克斯坦、康弘药业一注射剂药品出口缅甸、东北制药原料药出口欧洲、汇宇制药一注射剂药品出口法国、普利制药一注射剂药品出口以色列。汇宇制药三药品出口乌兹别克斯坦一、药物基本情况（一）多西他赛注射液品名称：多西他赛注射液剂型：注射剂规格：80mg/4ml；适应症：多西他赛注射液用于局部晚期或转移性乳腺癌、非小细胞肺癌，对头颈部癌、胰腺癌、胃癌、黑色素瘤、软组织肉瘤有一定的疗效。申请人：SeacrossPharmaceuticalsLtd. 上市许可号：DV/X/TO10653/05/24 （二）奥沙利铂注射液药品名称：奥沙利铂注射液剂型：注射剂规格：50mg/10ml；100mg/20ml；适应症：奥沙利铂注射液联合5-氟尿嘧啶（5-FU）和亚叶酸（FA）可用于治疗原发肿瘤完全切除后III期结肠癌的辅助治疗，以及转移性结直肠癌。申请人：SeacrossPharmaceuticalsLtd. 上市许可号：DV/X/TO10650/05/24 （三）盐酸伊立替康注射液药品名称：盐酸伊立替康注射液剂型：注射剂规格：40mg/2ml；100mg/5ml；适应症：盐酸伊立替康注射液适用于晚期结直肠癌患者的治疗、适用于联合西妥昔单抗治疗表皮生长因子受体表达RAS野生型转移性结直肠癌患者、适用于联合5-氟尿嘧啶、亚叶酸和贝伐单抗治疗结肠或职场转移性患者的一线治疗、适用于联合卡培他滨联合或不联合贝伐单抗的转移性结直肠癌患者的一线治疗。申请人：SeacrossPharmaceuticalsLtd. 上市许可号：DV/X/TO10652/05/24 二、药物其他相情况（一）多西他赛注射液多西他赛注射液用于局部晚期或转移性乳腺癌、非小细胞肺癌，对头颈部癌、胰腺癌、胃癌、黑色素瘤、软组织肉瘤有一定的疗效。公司多西他赛注射液研发成功后已进行了多国注册申报，分别已在中国、英国、德国、芬兰、法国、西班牙、瑞典、匈牙利、埃及等36个国家获得上市许可。截至目前，公司已在包含中国香港、孟加拉国、埃塞俄比亚等11个国家提交注册申请。（二）奥沙利铂注射液奥沙利铂注射液联合5-氟尿嘧啶（5-FU）和亚叶酸（FA）可用于治疗原发肿瘤完全切除后III期结肠癌的辅助治疗，以及转移性结直肠癌。公司奥沙利铂注射液研发成功后已进行了多国注册申报，分别已在中国、英国、匈牙利、阿联酋、加拿大、马来西亚、南非、埃及等16个国家获得上市许可。截至目前，公司已在包含南非、巴尔干半岛、文莱、乌兹别克斯坦等9个国家提交注册申请。（三）盐酸伊立替康注射液盐酸伊立替康注射液适用于晚期结直肠癌患者的治疗、适用于联合西妥昔单抗治疗表皮生长因子受体表达RAS野生型转移性结直肠癌患者、适用于联合5-氟尿嘧啶、亚叶酸和贝伐单抗治疗结肠或职场转移性患者的一线治疗、适用于联合卡培他滨联合或不联合贝伐单抗的转移性结直肠癌患者的一线治疗。公司盐酸伊立替康注射液研发成功后已进行了多国注册申报，分别已在中国、英国、保加利亚、新加坡、马来西亚、南非等26个国家获得上市许可。截至目前，公司已在包含中国香港、菲律宾、巴尔干半岛等10个国家提交注册申请。康弘药业药品出口缅甸一、药物基本情况产品名称：LUMITIN 生产商：成都康弘生物科技有限公司生产商地址：中华人民共和国四川省成都市金牛区蜀西路108号申请人名称：中国国际医药卫生有限公司申请人地址：中华人民共和国北京市朝阳区惠新东街4号剂型：注射液包装形式：含有 0.2ml 康柏西普眼用注射液的透明西林瓶、2个针头及1个注射器，并包装于一个纸盒治疗类别：血管内皮生长因子抑制剂规格与成分：每支西林瓶包含康柏西普眼用注射液 0.2ml （10mg/ml）销售类别：处方药注册证编号：2904EA04238 注册证有效期：2029 年 4 月 6 日二、药物其他相情况康柏西普眼用注射液是公司全资子公司康弘生物自主研发的具有完全自主知识产权的1类生物创新药，该产品能有效地与血管及组织中的VEGF结合，阻断由 VEGF介导的促进新生血管出芽和生长的信号传递。康柏西普眼用注射液于2013年获批用于治疗湿性年龄相关性黄斑变性（nAMD），2017年获批用于治疗继发于病理性近视脉络膜新生血管引起的视力损伤（pmCNV），2019年获批用于治疗糖尿病性黄斑水肿（DME）引起的视力损害，2022年获批用于治疗继发于视网膜静脉阻塞(RVO)(视网膜分支静脉阻塞(BRVO)或视网膜中央静脉阻塞(CRVO))的黄斑水肿引起的视力损伤。东北制药原料药出口欧洲一、药物基本情况原料药名称：ASCORBIC ACID/维生素C 证书编号：No. CEP 2022-066 - Rev 00 持有人：东北制药集团股份有限公司地址：中国辽宁省沈阳经济技术开发区昆明湖街8号发证机构：欧洲药品质量管理局（EDQM）二、药物其他相情况维生素C用于预防和治疗坏血病以及各种急、慢性传染疾病或其他疾病以增强机体抵抗力，病后恢复期、创伤愈合期及过敏性疾病的辅助治疗。汇宇制药药品出口法国一、药物基本情况药品名称：唑来膦酸注射液剂型：注射剂规格：5mg/100ml 适应症：本品主要用于治疗绝经后妇女以及成年男性的骨质疏松症，治疗绝经后妇女以及成年男性长期糖皮质激素治疗诱发的骨质疏松症，以及成人Paget’s骨病（变形性骨炎）。申请人： SeacrossPharma(Europe)Ltd. 上市许可号：NL54946 二、药物其他相情况唑来膦酸注射液主要用于治疗绝经后妇女以及成年男性的骨质疏松症，治疗绝经后妇女以及成年男性长期糖皮质激素治疗诱发的骨质疏松症，以及成人Paget’s 骨病公司唑来膦酸注射液研发成功后已分别在多国提交注册申报，包含中国，以及德国、丹麦、法国、芬兰、爱尔兰、意大利、西班牙、荷兰、葡萄牙、挪威、瑞典等11个欧洲国家。普利制药药品出口以色列一、药物基本情况（一）药品名称：注射用达托霉素（二）适应症：成人和儿童患者（1 至 17 岁）的复杂性皮肤和皮肤组织感染；成人患者由金黄色葡萄球菌引起的右侧感染性心内膜炎；成人及儿童患者（1 至 17 岁）的金黄色葡萄球菌血流感染（菌血症）。（三）剂型：注射剂（四）规格：500 mg （五）生产企业：海南普利制药股份有限公司二、药物其他相情况达托霉素是由Lilly（礼来）公司最初研究，Cubist 制药公司开发的环脂肽类抗生素，2003年9月12日，美国食品药品监督管理局经过快速审理程序批准注射用达托霉素制剂，商品名为 CUBICIN，临床用于治疗复杂性皮肤及皮肤组织感染与金黄色葡萄球菌引起的菌血症，目前注射用达托霉素已在全球广泛上市销售。普利制药的注射用达托霉素成功研发后，已相继提交了美国、荷兰、中国、英国、澳大利亚、德国和以色列等多个国家和地区的仿制药上市申请，属于共线生产品种。本品于2022年8月获得美国食品药品监督管理局的批准，2022年11月获得荷兰药物评价委员会的批准，2022年12月获得国家药品监督管理局的批准，2023年1月获得澳大利亚药物管理局的批准，2023年7月获得英国药品和健康产品管理局的批准，2024年3月获得德国联邦药物与医疗器械所的批准。

临床3期抗体药物偶联物申请上市临床结果

2024-05-16

·PRNewswire

Lindus Health Announces Cosmetics Clinical Trial with Acinonyx Bio to Evaluate an Alternative to Benzoyl Peroxide for Inflammatory Acne

NEW YORK, May 16, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has announced its collaboration with Acinonyx Bio, a biotechnology company that uses a unique mix of ingredients made from predominantly plants to kill different types of bacteria, fungi, and viruses effectively, in a cosmetics clinical trial to investigate their topical cream's ability to treat inflammatory acne. Inflammatory acne is characterized by red, swollen, and sore blemishes, providing physical discomfort and psychological stress due to its persistent nature and potential to leave permanent scarring. Acne is the most common skin condition in the US, affecting approximately 50 million people. This study aims to target Propionibacterium acnes (P. acnes), a bacterium that plays a significant role in the development of inflammatory acne. In in vitro studies, it was revealed Acinonyx Bio's topical cream, ACX, killed P. acnes as rapidly as does benzoyl peroxide, a widely used acne treatment. Benzoyl peroxide products, however, have recently garnered attention for containing a carcinogen, prompting some consumers to seek alternative therapies to manage their acne. ACX does not contain this associated carcinogen in its formulation, and it reduces sebum production, unclogs pores, and absorbs rapidly into the skin to lead to a more rapid clinical effect. The clinical trial will recruit patients with moderate to severe inflammatory acne and will be carried out under a decentralized clinical trial (DCT) model, providing patients with the flexibility to participate in this essential research within the comfort of their real-world environments. Participants will use the investigational product for a period of six weeks and provide photos for medical assessment as well as feedback on the effectiveness of the topical cream and their satisfaction with the product. Lindus Health, responsible for providing end-to-end study management, including protocol development, regulatory submissions, recruitment, monitoring, data management and more, will leverage their in-house virtual site and digital marketing capabilities to carry out patient recruitment via digital advertising. They will also design a dedicated study website with pertinent trial information including leveraging their proprietary eClinical platform, CitrusTM, for patients to easily complete pre-screening and eConsent. "Lindus Health's involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life," states Michael Young, co-founder of Lindus Health. "We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space." "We are optimistic about the development of our topical cream and the effect it will have on patients," says Alex Michalow, CEO at Acinonyx Bio. "We are incredibly excited to be working with Lindus Health to bring our study to life and aid in the overall journey of potentially bringing a safer alternative to the hands of individuals suffering from inflammatory acne." Positive results from this trial would further emphasize the potential of this novel topical cream in the utility of improving appearance in those who experience inflammatory acne. For more information, please visit About Lindus Health Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. Lindus Health does this thanks to a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), marrying a world-class clinical operations team with its unique software platform, and access to 30 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint they aim to improve health for everyone. They handle the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management. To date, ‍Lindus Health has delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company was named after James Lind, who pioneered the first clinical trial and treatment for scurvy, and co-founded by Michael Young, a former Special Adviser to the UK Prime Minister on Life Sciences, and Meri Beckwith, a former life sciences investor. Lindus Health has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm. About Acinonyx Bio Acinonyx Bio was founded by a practicing doctor who developed an antimicrobial technology that uses primarily food grade, mostly plant oil based, ingredients. The unique combination of ingredients shows high kill rates vs. numerous bacteria, fungi, and viruses. Media Contact: Jodi Perkins Amendola for Lindus Health [email protected] SOURCE Lindus Health

临床研究

2024-04-15

·赛柏蓝

117个「处方药」冲击3600亿市场！多个中成药在列...

编者按：本文来自米内网，作者苍穹；赛柏蓝授权转载，编辑yuki2023年中国零售药店终端（城市实体药店+网上药店）销售规模超3600亿元，同比增长6.35%。随着越来越多的处方药转为非处方药，零售药店市场将迎来新一轮扩容。01过百个处方药转OTC独家品种出圈，中成药霸屏院内市场支付“天花板”逐渐见顶，让院外市场的吸引力加速释放。随着医药行业发展提速和药品监管改革完善，近年来越来越多处方（RX）药转化为非处方（OTC）药，为患者提供了更多的用药选择和便利。2020年以来，国家药监局至少发布了47则处方药转OTC药的公告，合计117种药品（以产品名称统计），其中2020年有40个，2021年有39个，2022年有9个，2023年有18个，2024年至今有11个（按公告发布日计算），不乏阿胶胶囊、保妇康凝胶、小儿七星茶颗粒、维生素C咀嚼片等明星产品。117个转OTC的处方药中，独家品种有63个，其中中成药有49个，占比超七成；处方性质方面，双跨品种有40个，包括蒲地蓝消炎片、益母草软胶囊、布地奈德鼻喷雾剂、奥美拉唑镁肠溶片、乳果糖口服溶液等临床常用药。按治疗大类统计，呼吸系统疾病中成药、呼吸系统化学药及妇科用中成药在数量上领跑，分别占27个、16个和13个席位；消化系统疾病中成药、消化系统及代谢化学药分别占9个和8个，补气补血类中成药、肌肉-骨骼系统化学药则各占7个。2020年至今NMPA公布的处方药转OTC药名单注：带*为独家品种（含独家剂型）02蒲地蓝消炎、玻璃酸钠......猛攻3400亿市场，云南白药、齐鲁潜力可期受医保控费、合理用药及集采常态化等政策影响，处方药在院内市场频频承压，多个处方药纷纷转为OTC后，销售额及增速在零售药店终端屡创佳绩。以“清热解毒”功效著称的蒲地蓝消炎片，2022年在中国公立医疗机构终端仅有几千万的销售收入进账；而在零售药店终端销售额超过10亿元，同比增长37%，云南白药、方盛制药在市场份额上遥遥领先。可见，这类治疗普通感冒咳嗽的非抗生素产品，零售市场显然比院内市场更吃香。近年来中国零售药店终端蒲地蓝消炎片销售趋势（单位：万元）“人工泪液”玻璃酸钠滴眼液是治疗干眼症的主要药物之一。受集采影响，该药自2020年起在公立医疗机构终端销售额逐年下滑，至2023年上半年止跌回升，同比上涨26%；而零售市场规模则保持增长，其中在2023年网上药店终端销售额接近7亿元，市场份额首超城市实体药店终端。数据显示，玻璃酸钠滴眼液目前有37家企业拥有生产批文，齐鲁制药、扬子江药业、珍视明药业等23家企业通过/视同通过一致性评价。该药作为集采大品种，随着获批过评企业增多，院端市场利润已被高度压缩，如今由处方药转为OTC，相关药企有望伺机加速零售市场的开拓，填补集采影响下产品利润的缺口。玻璃酸钠滴眼液过评/视同过评企业情况维生素C咀嚼片主要用于预防坏血病，以及各种急慢性传染疾病和紫癜等辅助治疗。从销售渠道看，零售药店终端为该药的主战场，2022年销售额突破7亿元，同比涨逾70%；反观公立医疗机构终端，其销售市场则比较“低迷”。显然，对于一般维矿类保健品，考虑到购药便利性，零售药店终端无疑更受消费者欢迎，“处转非”更有利于该类产品市场规模的扩容。近年来中国零售药店终端维生素C咀嚼片销售趋势（单位：万元）数据显示，近年来中国零售药店终端化学药及中成药合计销售额逐年攀升；2021-2023年分别涨逾11%、13%和6%，2022年市场规模超过3400亿元，2023年再度突破3600亿元，未来前景值得期待。2020-2023年中国零售药店终端化学药及中成药总体销售趋势（单位：亿元）03“处转非”持续释放利好药企、药店及患者等多方受益伴随零售市场快速增长，不难窥见，处方药转OTC对于药企、药店以及患者而言，都是利好。对医药企业而言，在其原研药专利到期后，面临仿制药激烈的价格竞争，会出现院内销售骤降的情况，即专利悬崖；叠加近年医保控费、集采降价等政策冲击，一些原研药甚至因此退出市场。处方药转为OTC后，一方面能够使产品生命周期得到延长，另一方面能使药品受众拓宽，药企能获取更多收益，也拉动公司其他产品销售。对终端药店而言，非处方药品类越多，越能满足消费者的需求。“处转非”药品在药店可以直接购买，有望增加产品销售量，扩大市场份额。若部分药品在处方药阶段就已经有良好市场基础，“处转非”进入更灵活的销售渠道后，将为相关企业带来更优的利润及发展机会。对患者而言，根据《药品管理法》对处方药、非处方药甲类/乙类的分类管理要求，药品由处方药变为OTC之后，患者不需要医生处方就能在线下药店和线上电商平台购药，购药渠道增加，购药更加便捷，尤其利好部分需要长期购药的患者。此外，在临床诊治方面，对部分小病来说，患者能通过自我诊疗、自行服药等方式达到治愈的效果，院端资源也更能向大病、难病患者集中。总体而言，处方药转为OTC是一种符合时代发展和社会需求的趋势，也是一种有利于提高医疗效率和患者福祉的举措。不过，非处方药并不等于无风险或无限制，仍然需在科学、规范的基础上使用。END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联